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Abstract Keloids are benign fibroproliferative diseases of unknown aetiology.
They occur as a result of derangement of the normal wound healing process in sus-
ceptible individuals. Although several factors have been postulated in the aetio-
pathogenesis of this condition, there has been growing evidence to suggest a role
for Transforming Growth Factor beta (TGFb) family members in its pathogenesis.
TGFb has also been found to be associated with fibrotic diseases affecting different
organs of the body including liver, kidney, lung as well as skin. In this review article,
we will discuss the morphology and mechanism of action of TGFb and its isoforms
and present the most up to date literature discussing the role of TGFb isoforms,
their receptors, and intracellular signalling pathways (the SMAD pathway) in the
pathogenesis of keloid disease. Understanding the role of TGFb in keloid disease
could lead to the development of clinically useful therapeutic modalities for treat-
ment of this condition.
ª 2006 Published by Elsevier Ltd on behalf of Surgical Associates Ltd.Introduction
Keloid scars are fibroproliferative dermal lesions
that commonly occur following any form of trauma
to the dermis such as surgery or burns.1,2 Typically,
keloid scars extend beyond the margins of the
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doi:10.1016/j.ijsu.2006.04.007original wound and spread by invasion of the neigh-
bouring skin rather than expansion (Fig. 1). Histo-
logically, keloids are characterised by haphazard
deposition of thick hyalinised eosinophilic collagen
fibres in a mucinous extracellular matrix (ECM)
with abundant lymphocytes and eosinophils and
few macrophages.1e6 A characteristic feature of
a keloid disease (KD) is the presence of collagen
nodules consisting of dense mass of collagen and
fibroblasts.7 KD shows an elevated collagen mRNA
expression,8 elevated levels of propyl-4 hydroxylasen behalf of Surgical Associates Ltd.
TGFb and keloid disease 279activity and an elevated fibronectin synthesis,9 all
of which result in higher level of collagen deposition
than normal.
KD is thought to arise as a result of derangement
of normal wound healing process. Wound healing is
the end result of a group of cellular and humoral
events orchestrated with the aim of achieving the
normal homeostasis. The classical stages of wound
healing include inflammation, epithelialisation,
formation of granulation tissue, neovascularisa-
tion, wound contraction and scar maturation with
ECM reorganisation.10 A number of growth factors
such as transforming growth factor beta (TGFb),
interleukins and insulin like growth factors (IGF)
and others have been implicated as important fac-
tors involved in the normal wound healing process.
These cytokines have all been thought to be in-
volved in scar formation.11e13
A central event in dermal repair is the release of
cytokines in response to injury. There is overwhelm-
ing evidence pointing to TGFb as a key cytokine
that initiates and terminates tissue repair and
whose sustained production underlies the develop-
ment of fibrosis. It induces ECM components, but
overproduction of TGFb can result in excessive
deposition of scar tissue and fibrosis.14 This review
Figure 1 Keloid scar in the posterior aspect of an ear.will aim to briefly introduce the TGFb superfamily
and their signalling pathways and then describe in
detail the importance of this significant fibrotic
cytokine in development of fibrotic diseases such
as KD.15
Transforming growth factor
beta (TGFb)
TGFb is a multifunctional natural polypeptide that
belongs to a superfamily of cytokines. In mammals,
this super family comprises of over 30 proteins
including 3 isoforms of TGFb namely TGFb1, b2 and
b3, 3 forms of activins and over 20 bonemorphogenic
proteins (BMPs).16e30 It is released from the alpha
granules of platelets by degranulation with throm-
bin. It is secreted as an inactive latent form called
Latent TGFb (L-TGFb), which is a large 390e412
amino acid precursor protein and is activated by pro-
teolytic cleavage between amino acids 278 and 279
into active TGFb and Latency associated peptide
(LAP).20 The active TGFb acts on its target cells by
combining with transmembrane serine/threonine
kinase TGFb receptors.29 Four different types of
TGFb receptors, present virtually in all parts of the
body, have been identified. Types I and II are the
most active receptors involved directly with signal
transduction and two accessory receptors, namely
Type III or betaglycan receptor and Endoglin, which
act by presenting the ligands to Type I or II receptors,
help in the process of signal transduction.28 Each
TGFb isoform (TGFb1, -b2, and -b3) differs in its bind-
ing affinity for TGFb receptors. TGFb act by binding
with type II serine threonine kinase receptor which
then transphosphorylates and activates type I recep-
tor. The type I receptor then transduces intracellular
signalling pathways by phosphorylating the intracel-
lular signal pathways by interacting with certain
intracellular proteins called SMADs in various combi-
nations which in turn stimulates transcription of
genes,31 which affect almost all phases of wound
healing. Smads get their name from related genes
‘‘Sma; gene similar to Mothers Against’’ and ‘‘Mad;
gene Mothers Against Decapentaplegic’’ isolated
from round worm Caenorhabditis elegans and the
fly Drosophila melanogaster, respectively, both of
which were found to be responsible for intracellular
signal transmission by TGFb.30 The SMAD complex
interacts in the nucleus with transcription factors
to regulate the transcription of TGFb responsive
genes andmediate theeffects of TGFb at the cellular
level.32 Several different forms of SMADs have so far
been identified in mammals and have been classified
into different functional classes such as R-Smads or
receptor regulated Smads consisting of Smad 1, 2, 3,
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of Smad 4 and I-Smads, or Inhibitory Smads consist-
ing of Smad 6 and 7.17 After binding with TGFb
receptor the TGFb receptor kinase phosphorylates
Smad 2 and 3, which are the receptor regulated
Smads, which then activate Smad 4 which is the
Common partner Smad, which translocates to the
nucleus.36 For transcriptional activation, SMADs
require binding of additional transcription factors
such as activator protein one (AP-1) and simian virus
40 promoter factor one (Sp-1). These signalling
pathways have been shown to regulate type I colla-
gen gene expression.31e34 All of the above signalling
pathways help to orchestrate the events of wound
healing ultimately leading to accumulation of ECM
in granulation tissue.35 The negative feedbackmech-
anismwhich regulates the signal transduction acts in
two ways. In the first instance, the continued phos-
phorylation of R-Smads is competitively inhibited
by the Inhibitory Smads; Smad 6 and 7 and the other
mechanism is by ubiquitination of Smad 3, which has
completed the transcription process by ligases.36
TGFb and fibrotic diseases
Fibrotic diseases are a group of diseases with very
limited effective treatment. They are characterised
by excessive scarring secondary to excessive pro-
duction, deposition or contraction of ECM.36 TGFb, es-
pecially the TGFb1 isoform, is a keymediator of tissue
fibrosis and has been implicated in many fibrotic
diseases like pulmonary fibrosis, systemic sclerosis,
keloids and hypertrophic scars, and fibrotic disease of
kidney and liver.14 An animal model by Shah et al.25
demonstrated the profibrotic activity of TGFb1e2
and antifibrotic effect of TGFb3, and suggested
that the way forward for treatment of fibrotic con-
ditions and scarring is either by blocking the effects
of TGFb1 and TGFb2 or administration of TGFb3.
25
This profibrotic activity of TGFb could be due to
their ability to induce ECM proteins in mesenchymal
cells and also by production of protease inhibitors,
which inhibit the enzymatic breakdown of ECM.37
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TGFb isoforms
The three TGFb isoforms identified in mammals;
TGFb1, b2 and b3 are thought to have different
biological activities in wound healing. TGFb1 and
TGFb2 are believed to promote fibrosis and scar for-
mation,38e42 whereas TGFb3 has been shown to be
either scar inducing43 or reducing,25 depending on
the study. Due to their profibrotic activity, TGFb1andb2 isoforms havebeenproposed to be significant
in the pathogenesis of KD. Several studies havedem-
onstrated differences in action of keloid fibroblasts
compared to normal dermal fibroblasts as well as
the association of TGFb in KD pathogenesis.
TGFb1 isoform
TGFb1 stimulates growth and collagen secretion
and is thought to be integral to keloid formation.44
TGFb1 results in stimulation of total protein syn-
thesis in normal dermal fibroblasts but not in
keloid fibroblasts, suggesting that the TGFb regula-
tory pathway is altered in keloid fibroblasts. How-
ever, both keloid and normal fibroblasts treated
with TGF b1 exhibit accelerated fibronectin biosyn-
thesis, indicating that keloid cells can respond to
TGF b1. TGFb1 induces an increase in fibronectin
biosynthesis more rapidly in keloid fibroblasts, sug-
gesting modification of this regulatory pathway.
The TGFb1-mediated increase in keloid fibronectin
production is independent of the steroid regula-
tory pathway for fibronectin, which accelerates
synthesis by means of a post-transcriptional mech-
anism. Thus, TGFb1 stimulation of fibronectin
production in keloid cells is likely to involve a tran-
scriptionalmechanismand keloid overproduction of
ECM components may be due to an inherent modifi-
cation of the TGFb regulatory programme.45 There
is a unique sensitivity of keloid fibroblasts to TGF
b1 causing an increase in absolute collagen synthesis
in keloid fibroblasts indicating a differential
response between keloid and normal fibroblasts.
This response occurs at the pretranscriptional level
as there is corresponding increase in procollagen
type I mRNA levels.46
TGFb1 protein and mRNA have been detected
in areas active in type I and type VI collagen
gene expression, indicating that TGFb1 gene
is transcribed and the corresponding protein is
deposited in areas of elevated collagen gene
expression, including microvascular endothelial
cells of keloid tissue. It is suggested that the initial
step in the development of fibrotic reaction in
keloids involves the expression of the TGFb1 gene
by the neovascular endothelial cells, thus activat-
ing the adjacent fibroblasts to express markedly
elevated levels of TGFb1, as well as type I and VI
collagen genes.44
The effect of TGFb1 on the rate of collagen syn-
thesis in keloid (KF), hypertrophic scar (HSF) and
normal skin fibroblasts was studied by using fibro-
blasts cultured in three-dimensional fibrin-gel
matrices in the presence or absence of TGFb or
anti-TGFb neutralising antibody. They demonstrated
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cially during the proliferative phase of wound heal-
ing, but their rate of collagen overproduction is
similar to that by HSFs.47 Another study demon-
strated that keloid fibroblasts showed a 3-fold
increase in production of type 1 collagen, 6-fold
increase in matrix metalloproteinase one (MMP1),
2.4-fold increase in MMP2, 2-fold increase in
production of tissue inhibitor of metalloproteinase
one (TIMP1) and 2.5-fold increase in migratory
activity compared to normal fibroblasts. Addition
of TGFb1 to the culture media augmented release
of type-1 collagen and a decrease in MMPs; in con-
trast, addition of anti-TGFb showed the opposite
result thus reinforcing the proposed theory for the
role of TGFb in keloid disease.48 Tranilast, an anti-
allergic drug, has an inhibitory effect on collagen
synthesis in cultured fibroblasts from keloid and
hypertrophic scar tissues. This inhibition occurs by
release of TGFb1 from the fibroblasts but not by
inhibiting prolyl hydroxylase (the rate-limiting
enzyme in collagen synthesis) activity.47
TGFb2 isoform
An in vivo model of human scar xenografts, main-
tained in congenitally athymic, asplenic ‘‘nude’’
rats, examined endogenous TGFb2 levels in keloids
and burn hypertrophic scars treated with TGFb2
and TGFb2 antibodies. The results demonstrated
that exogenous TGFb2 results in a significant in-
crease in endogenous TGFb2, collagen I, and colla-
gen III production in human proliferative scars. By
contrast, exogenous addition of anti-TGFb2 anti-
body significantly decreased endogenous TGFb2,
collagen I, and collagen III production. This study
supported a causative role for TGFb2 in the forma-
tion of proliferative scars and suggests that
anti-TGF b2 antibody may be a new potential
anti-scarring agent.42
Using a similar in vivo animal model of prolifer-
ative scarring, the effects of TGFb2 on different
scars were examined. Proliferative scar specimens
were implanted into athymic, asplenic nude rats
and isolated in sandwich island flaps based on the
superficial inferior epigastric pedicle. After estab-
lishment of the transferred flap, the scars were in-
jected with varying doses of TGFb2. Fibroblasts
from the explanted biopsies and the original scars
were grown in cell culture. Cell proliferation studies
were performed and the results compared. A dose
response to TGFb2 was noticed. Keloid scars demon-
strated the greatest cell proliferation kinetics and
were significantly faster than non-burn and burn
hypertrophic scars. The combination of prolifera-
tive scar fibroblast abnormal response to TGFb2stimulation and the elevated levels of this cytokine
more accurately controls the process of keloid and
burn hypertrophic scar formation.49,50 In another
study, using an in vitro fibroblast-populated colla-
gen lattice (FPCL) to evaluate fibroblast activation
by measuring contraction of the lattice over time,
it was shown that upon exogenous administration
of TGFb2 to fibroblasts from keloid, burn hypertro-
phic scars and normal skin the fibroblasts from
keloid showed a significant increase in contraction
and this effect was countered by addition of exoge-
nous TGFb2 antibody.
51
TGFb isoform expression was studied in keloids
at the protein level using Western blot analysis and
showed that TGFb1 and b2 expression were raised
in keloid fibroblast cultures compared with normal
human dermal fibroblast cultures. In contrast, the
TGFb3 protein was comparable in both the normal
and keloid cell lines. These findings demonstrated
increased TGFb1 and b2 protein expression in ke-
loids, relative to normal human dermal fibroblasts,
thus further supporting the roles of TGFb1 and b2
as fibrosis-inducing cytokines.52,53
TGFb receptors
While keloid fibroblasts have a unique sensitivity to
TGFb compared to normal fibroblasts, Chin et al.55
showed that the altered response of keloid fibro-
blasts to TGFb is because of changes that occur
at the receptor level. They studied the levels of
TGFb receptors as well as SMAD 3 in keloid derived
fibroblasts compared to normal human derived fi-
broblasts and showed that there is an increased
expression of TGFb types I and II receptors in ke-
loid fibroblasts. Bock et al.54 studied the expres-
sion of TGFb1,2,3 as well as types I and II TGFb
receptor mRNAs and showed that the expression
of type I TGFb receptor mRNA was significantly
reduced in hypertrophic scars, and that of type II
receptor reduced in Keloid scars, thus resulting in
an increased TGFbRI/TGFbRII ratio in keloid com-
pared to hypertrophic scars. Expression levels of
TGFb I and II receptors were investigated between
keloid and normal human dermal fibroblasts and
the results showed that their expression is signifi-
cantly raised in keloid tissue.55
Transcription factors
AP-1 transcription factors play an important role in
type I collagen production by regulating its signal-
ling pathways and plays a role in TGFb induced
extracellular matrix production. Based on this, Kim
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tors play a role in keloid pathogenesis. They stud-
ied the characteristics of keloid and normal dermal
fibroblasts by blocking the AP-1 transcription fac-
tors using AP-1 decoy oligodeoxynucleotides
(ODN). Their results showed that TGFb induced
collagen production was significantly suppressed
in keloid fibroblasts treated with AP-1 decoy
ODN. This is an in vitro study and further studies
are required to prove the results in vivo and to
prove the efficacy of AP-1 decoy ODN to suppress
progression of keloid disease.34SMAD intracellular signalling pathways
Recent studies have laid emphasis on the possibility
of TGFb intracellular signalling pathways especially
the SMAD pathway in the pathogenesis of keloid
disease. Phan et al.56 compared the characteristics
of SMAD intracellular signalling pathways between
keloid fibroblast and normal dermal fibroblast
cultures and demonstrated that SMAD3 was over
expressed in keloid fibroblasts co cultured with
keloid keratinocytes thus suggesting its role in ke-
loid pathogenesis. In contrast, expression of SMADFigure 2 This diagram aims to demonstrate potential sites where pathology (e.g. mutations present in TGFb family
members such as isoforms, receptors, transcription factors or signalling molecules) could result in keloid disease
formation. Abbreviations: TGFb, transforming growth factor beta; L-TGFb, latent TGFb; LAP, latency associated pep-
tide; R SMAD, receptor regulated SMAD (Similar to Mothers Against Decapentaplegic/Drosophila gene); Co SMAD, com-
mon-partner SMAD; I SMAD, inhibitory SMAD; SP1, promoter specific transcription factor 1; AP1, activating protein 1.
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compared to normal fibroblasts demonstrated that
the expression of SMAD 3 was lower compared to
normal skin fibroblasts. The expression of Inhibitory
SMADs 6 and 7 mRNA were also reduced. They con-
cluded that the failure of inhibition of TGFb signal-
ling by the inhibitory SMADs, as the cause of keloid
formation.57
The potential sites in the TGFb signalling pathway
where mutations in TGF beta family members such
as isoforms, receptors, transcription factors or
signalling molecules may occur and could result in
keloid disease formation is summarised in Fig. 2.
Although a number of studies have been carried
out with the aim of investigating the genetic basis
of keloid disease none to date have shown a signifi-
cant statistical association between TGF b1,
58 b2,
27
b3,
59 as well as TGFb receptor60 gene polymorphisms
with keloid disease. Further studies are required to
confirm the role of TGFb and its signalling pathways
in the pathogenesis of keloid disease.
Potential future therapies
Understanding the mechanisms of TGFb mediated
up-regulation of collagen gene expression in keloids
should provide novel opportunities for treatment of
this fibrotic disorder.61 Several studies to date have
suggested apossible role for TGFb in keloid scarring.
Attempts to reduce pathological scarring include
ways to either block or to counter the biological ef-
fects of TGFb.62 Anti-TGFb1 antibody may show
therapeutic potential for treatment of keloids ei-
ther by inhibition of collagen synthesis by blocking
TGFb1 or accelerated degeneration of types 1 and
3 collagens which are abundant in keloid tissue.49
Suppression of SMAD3 signalling results in inhibition
of keloidfibroblastswhichmayproveuseful in treat-
ment of keloid disease.56 AP-1 decoy ODN is shown
to abolish the TGFb induced type I collagen gene
expression andmay also prove relevant in the treat-
ment of keloid disease.34
Conclusion
Keloid disease is a benign but progressive form of
skin fibrosis and can be a cause of major morbidity.
Keloid disease is thought to involve the fundamen-
tal processes of wound healing cascade.13 TGFb iso-
forms have been linked to a wide variety of fibrotic
diseases. Importantly, TGFb has been implicated in
the pathogenesis of keloid disease. Understanding
the actions of TGFb in keloid disease could lead
to the development of clinically useful anti-fibroticagents. Understanding the processes involved in
keloid scar formation is of paramount importance
in the treatment of this physically as well as psy-
chologically disturbing disorder.
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